Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials-Reference-Cited by-同舟云学术

Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials

Published:2016-01-25 Issue:3 Volume:7 Page:283-288
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Dhar T. G. Murali¹,Xiao Hai-Yun¹,Xie Jenny¹,Lehman-McKeeman Lois D.¹,Wu Dauh-Rurng¹,Dabros Marta¹,Yang Xiaoxia¹,Taylor Tracy L.¹,Zhou Xia D.¹,Heimrich Elizabeth M.¹,Thomas Rochelle¹,McIntyre Kim W.¹,Warrack Bethanne¹,Shi Hong¹,Levesque Paul C.¹,Zhu Jia L.¹,Hennan James¹,Balimane Praveen¹,Yang Zheng¹,Marino Anthony M.¹,Cornelius Georgia¹,D’Arienzo Celia J.¹,Mathur Arvind¹,Shen Ding Ren¹,Cvijic Mary Ellen¹,Salter-Cid Luisa¹,Barrish Joel C.¹,Carter Percy H.¹,Dyckman Alaric J.¹

Affiliation:

1. Research and Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5b00448

Reference26 articles.

1. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

2. Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists

3. The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors